Table 2.

Compounds/compound groups fulfilling the feasibility criteria

Drug/drug group	Genes
Antidepressants (e.g., mirtazapine)	HTR2A
Antihistamines (e.g., diphenhydramine)	CHRM2, CHRM3, CHRM5, HRH1
Antimuscarinics (e.g., fesoterodine)	CHRM2, CHRM3, CHRM5
Aprepitant	TACR1
Ergot alkaloids (e.g., ergotamine)	HTR2A
Fasoracetam	GRM1, GRM5
Memantine	GRIN2A
Antipsychotics	CHRM2, CHRM3, CHRM5, GRIN2A, HRH1, HTR2A
Opioids (e.g., morphine)	GRIN2A

Note on the feasibility criteria: IPA (Ingenuity Systems indicated the existence of therapeutic compounds for 15 of the candidate targets (see Table S1 for all candidate targets). The following priority criteria were applied with respect to suitability in the context of a pharmacological intervention study in Switzerland: 1, existing registration as therapeutic compound by the Swiss Agency for Therapeutic Products (Swissmedic) and availability on the Swiss market; 2, acceptable side effects profile [i.e., no major side effects such as nephrotoxicity, neurotoxicity or myelotoxicity (e.g., anticancer drugs were not considered)]; and 3, favorable application mode (e.g., oral administration was prioritized over i.v. or s.c. medication). Application of these priority criteria to the list of existing compounds (see Table S2 for all existing compounds) resulted in nine compounds/compound groups (corresponding to nine genes, shown in this table).